WEST LAFAYETTE, Ind., March 20, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that data from the PROCEED Study will be presented at the 2015 Annual Meeting on Women's Cancer in Chicago on Saturday, March 28 in Chicago.
The presentation materials will be available on Endocyte's website following the presentation at the conference.
Presentation is as follows:
|Title:||A Randomized Double-Blind Phase 3 Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD/DOXIL®/CAELYX®) in Combination|
|Versus PLD in Participants with Platinum-Resistant Ovarian Cancer|
|Time:||10:58 a.m. CDT|
|Location:||Hilton Chicago, International Ballroom|
|Presenter:||Amit M. Oza, MD, Princess Margaret Hospital, Toronto, ON, Canada|
About Vintafolide (EC145)
Vintafolide is an investigational proprietary, injectable, SMDC consisting of folate (vitamin B9) linked to a potent vinca alkaloid chemotherapy agent, desacetylvinblastine hydrazide (DAVLBH). Vintafolide is designed to target the chemotherapy agent to rapidly growing cancer cells that actively take up folate via the folate receptor. The folate receptor is expressed in a wide variety of cancers including ovarian cancer and non-small cell lung cancer.
Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.
CONTACT: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, firstname.lastname@example.org